Gastric Cancer, GastroEsophageal Cancer
Conditions
Keywords
Gastric cancer, GastroEsophageal Cancer, Albumin-bound Paclitaxel, PD-1 inhibitor
Brief summary
This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of Albumin-bound Paclitaxel Plus SHR-1210 （PD-1 inhibitor）Versus Albumin-bound Paclitaxel as Second-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
Detailed description
This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of an immune checkpoint inhibitor in patients with advanced or recurrent gastric and esophagogastric junction adenocarcinoma, including two arms to compare the efficacy and safety of Albumin-bound Paclitaxel Plus SHR-1210 （PD-1 inhibitor）regimen and Albumin-bound Paclitaxel single-agent regimen in second-line treatment.
Interventions
DRUGAlbumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;SHR-1210 200mg, ivdrip,d1,Q21d.
DRUGAlbumin-bound Paclitaxel
Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;
Sponsors
Huazhong University of Science and Technology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Age of 18-70 years. 2. Second line treatment for cytological or histological diagnosis of recurrent or metastatic gastric and esophagogastric adenocarcinoma. Disease progression after adjuvant therapy within 6 months is eligible. 3. ECOG performance status of 0-2. 4. Estimated life expectancy of at least 3 months. 5. Bone marrow function: white blood cell count≥3.0×109 /L, absolute neutrophil count(ANC) ≥1.5×109 /L, platelet count(PLT) ≥90×109 /L, hemoglobin(HB) ≥90 g/L. 6. Left ventricular ejection fraction (LVEF) ≥ 50%. 7. Liver and kidney function: Creatinine(Cr)≤1.5 x upper limit of normal range(ULN); alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤2.5 x upper limit of normal range (ULN), or ≤5 x upper limit of normal range (ULN)when with hepatic metastases，total bilirubin (TBIL)≤1.5 x upper limit of normal range (ULN), or≤2.5 x upper limit of normal range (ULN) when with Gilbert's syndrome. 8. Any acute, clinically significant treatment-related toxicity caused by previous treatment must have been reduced to less than or equal to grade 1, except hair loss. 9. Able and willing to comply with the study plans in this protocol and sign the informed consent.
Exclusion criteria
1. uncontrollable infections or have received systematic antibiotic treatment within 72 hours before enrollment. 2. Any abnormal bone marrow hyperplasia or other abnormal hematopoietic function. 3. Have a second malignancy within 5 years prior to registration except for cured carcinoma in situ of cervix uteri, non-melanoma skin cancer. 4. Patients with symptomatic brain metastases. 5. Allergic to the chemotherapy drugs or the materials in this study. 6. Suffering from mental or nervous system disorders and unable to cooperate. 7. Pregnant or nursing female patients. Men and women of reproductive age are unwilling to take reliable contraceptive measures during the study. 8. Active autoimmune disease, history of autoimmune disease, use of corticosteroids or immunosuppressants, or use of hormone replacement therapy, such as thyroxine, insulin, etc. 9. Live vaccine was administered within 30 days before enrolment (injectable seasonal influenza vaccine is allowed as it is inactivated). 10. Patients with other diseases not suitable for enrolment, such as active tuberculosis, hepatitis B (after treatment, hepatitis B virus titer HBV-DNA \<500IU/ml, and liver function is normal, but cannot be combined with hepatitis C), hepatitis C, uncontrolled electrolyte disorders ,pericardial effusion, pleural effusion and abdominal effusion, etc. 11. Have participated in other clinical trials within 30 days prior to this study. 12. History of organ transplantation. 13. Patients that researcher consider cannot sign informed consent or complete the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| objective response rate(ORR) | up to 12 months | The rate of participants that achieve either a complete response (CR) or a partial response (PR).Higher rate of ORR indicates better treatment effect. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | up to 9 months | Time from the start of treatment to progression of disease or death.Higher rate of 9m PFS in statistic analysis means better outcome. |
| Overall survival (OS) | up to 12 months | Time from the start of treatment until death due to any reason.Increased rate of 12m OS compared to the other arm indicates more benefit from the treatment regimen. |
| Safety as measured by number and grade of adverse events | up to 12 months | Summary adverse events according to NCI-CTCAE 5.0 |
| patient-reported outcomes (PROs) | up to 12 months | Patient-reported outcomes according to EQ-5D questionnaires. |
Countries
China
Outcome results
None listed